ozagrel

Ozagrel is a small molecule antiplatelet agent classified as a thromboxane A2 synthase inhibitor. It acts by selectively inhibiting the enzyme thromboxane A2 synthetase, thereby blocking the biosynthesis of thromboxane A2 (TXA2), a potent vasoconstrictor and promoter of platelet aggregation. This mechanism reduces platelet aggregation and vascular constriction without affecting prostacyclin (PGI2) synthesis. Ozagrel has been used primarily in the treatment of acute ischemic stroke, cerebral ischemia, and bronchial asthma due to its antiplatelet and anti-inflammatory properties. It was first approved in 1988 and is available in oral and intravenous formulations[1][3][4][5][6][7][8].

Brand names

PulmozaStrozagelOzafloCataclotOzac

Other names

ozagrelum(E)-p-(Imidazol-1-ylmethyl)cinnamic acid3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid